Member
OrthoTreat
OrthoTreat is dedicated to advancing bone regeneration through innovative solutions that enhance the body's physiological healing mechanisms. Their unique approach, OsteoRegulation, focuses on optimizing biological processes rather than merely providing materials for bone formation, aiming for faster, better, and stronger healing outcomes.
Industries
life-science
medical
pharmaceutical
Nr. of Employees
small (1-50)
OrthoTreat
WeWork Hazerem, 7 Hapelech st. Tel Aviv Jaffa, Israel
Products
ModulX (dual‑drug bone regeneration therapy)
A dual‑active therapeutic formulation combining a statin‑class small molecule and a CB2 receptor agonist delivered via a controlled‑release system to modulate inflammation, stimulate osteogenesis and support bone healing across inflammatory, reparative and remodeling phases.
ModulX (dual‑drug bone regeneration therapy)
A dual‑active therapeutic formulation combining a statin‑class small molecule and a CB2 receptor agonist delivered via a controlled‑release system to modulate inflammation, stimulate osteogenesis and support bone healing across inflammatory, reparative and remodeling phases.
Expertise Areas
- Bone regeneration
- Fracture healing
- Osseointegration
- Osteoporosis therapeutics
Key Technologies
- Dual‑drug combination therapy
- Controlled‑release drug delivery systems
- Statin‑based osteogenic modulation
- CB2 receptor agonist modulation
Key People
Dr. Tami Ehrmann Barr
Co-founder & Chief Scientific Officer
Dr. Tami Ehrmann Barr
Co-founder & Chief Scientific Officer